Risk Factor and Clinical Outcome of Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: The development of bronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic stem cell transplantation (HSCT) deteriorates patients’ quality of life. This study aimed to analyze the prevalence, clinical features, risk factors and prognosticfactors of BOS. Materials and Methods: This retrospective study included patients who underwent allogeneic HSCT from January 2002 to December2008 and survived for ≥100 days after transplantation. Results: Of 860 patients who survived for ≥100 days, 36 (4.2%) met the diagnostic criteria. The duration of BOS development after transplantation was 466.00 (284.00–642.75) [median (interquartile range)] days. The risk factor for the development of BOS was peripheral blood as the stem cell source with a hazard ratio (HR) of 2.550 [95% confidence interval (CI): 1.274–5.104, p=0.008]. In multivariate analysis, pretransplant FEV1/FVC (HR: 0.956, 95% CI: 0.921–0.993, p=0.020) and time from HSCT to diagnosis of BOS (HR: 0.997, 95% CI: 0.994–0.999, p=0.009) were independent prognostic factors associated with mortality. Conclusion: Peripheral blood as a stem cell source is a risk factor for the development of BOS. A decreased pretransplant FEV1/FVC and shorter duration of time from transplantation to diagnosis of BOS are poor prognostic factors for BOS.
Abstract
Purpose: The development of bronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic stem cell transplantation (HSCT) deteriorates patients’ quality of life. This study aimed to analyze the prevalence, clinical features, risk factors and prognosticfactors of BOS. Materials and Methods: This retrospective study included patients who underwent allogeneic HSCT from January 2002 to December2008 and survived for ≥100 days after transplantation. Results: Of 860 patients who survived for ≥100 days, 36 (4.2%) met the diagnostic criteria. The duration of BOS development after transplantation was 466.00 (284.00–642.75) [median (interquartile range)] days. The risk factor for the development of BOS was peripheral blood as the stem cell source with a hazard ratio (HR) of 2.550 [95% confidence interval (CI): 1.274–5.104, p=0.008]. In multivariate analysis, pretransplant FEV1/FVC (HR: 0.956, 95% CI: 0.921–0.993, p=0.020) and time from HSCT to diagnosis of BOS (HR: 0.997, 95% CI: 0.994–0.999, p=0.009) were independent prognostic factors associated with mortality. Conclusion: Peripheral blood as a stem cell source is a risk factor for the development of BOS. A decreased pretransplant FEV1/FVC and shorter duration of time from transplantation to diagnosis of BOS are poor prognostic factors for BOS.
참고문헌 (29)
- Williams KM, "Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation", JAMA, 302, pp.306~314 (2009)
- Chien JW, "Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation-an increasingly recognized manifestation of chronic graft-versus-host disease", Biol Blood Marrow Transplant, 16(1Suppl), pp.S106~S114 (2010)
- Chien JW, "Preventing and managing bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplantation", Expert Rev Respir Med, 5, pp.127~135 (2011)
- Pandya CM, "Bronchiolitis obliterans following hematopoietic stem cell transplantation: a clinical update", Clin Transplant, 24, pp.291~306 (2010)
- Santo Tomas LH, "Risk factors for bronchiolitis obliterans in allogeneic hematopoietic stem-cell transplantation for leukemia", Chest, 128, pp.153~161 (2005)
- Clark JG, "Thomas ED. Risk factors for airflow obstruction in recipients of bone marrow transplants", Ann Intern Med, 107, pp.648~656 (1987)
- Holland HK, "Bronchiolitis obliterans in bone marrow transplantation and its relationship to chronic graft-v-host disease and low serum IgG", Blood, 72, pp.621~627 (1988)
- Clark JG, "Obstructive lung disease after allogeneic marrow transplantation. Clinical presentation and course", Ann Intern Med, 111, pp.368~376 (1989)
- Yokoi T, "Broncho-bronchiolitis obliterans as a complication of bone marrow transplantation: a clinicopathological study of eight autopsy cases. Nagoya BMT Group", Virchows Arch, 431, pp.275~282 (1997)
- Afessa B, "Bronchiolitis obliterans and other late onset non-infectious pulmonary complications in hematopoietic stem cell transplantation", Bone Marrow Transplant, 28, pp.425~434 (2001)
- Chien JW, "Airflow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation", Am J Respir Crit Care Med, 168, pp.208~214 (2003)
- Dudek AZ, "Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes", Biol Blood Marrow Transplant, 9, pp.657~666 (2003)
- Chien JW, "Implications of early airflow decline after myeloablative allogeneic stem cell transplantation", Bone Marrow Transplant, 33, pp.759~764 (2004)
- Yoshihara S, "Lower incidence of Bronchiolitis obliterans in allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning compared with myeloablative conditioning", Bone Marrow Transplant, 35, pp.1195~1200 (2005)
- Choi MH, "Acute pulmonary complications in patients with hematologic malignancies", Radiographics, 34, pp.1755~1768 (2014)
- Jung Im Jung, "Bronchiolitis Obliterans after Allogenic Bone Marrow Transplantation: HRCT Findings", Korean Journal of Radiology, 5(2), pp.107~113 (2004), 대한영상의학회
- Oh JK, "Multidetector row computed tomography quantification of bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation: a pilot study", J Thorac Imaging, 28, pp.114~120 (2013)
- Kim TY, "CT and MRI evaluation of cardiac complications in patients with hematologic diseases : a pictorial review", Int J Cardiovasc Imaging, 31(Suppl 2), pp.159~167 (2015)
- Jung JI, "Pulmonary tuberculosis after hematopoietic stem cell transplantation: radiologic findings", Thorac Imaging, 24, pp.10~16 (2009)
- Hwang SS, "The value of CTguided percutaneous needle aspiration in immunocompromised patients with suspected pulmonary infection", AJR Am J Roentgenol, 175, pp.235~238 (2000)
- Cho BS, "Feasibility of NIH consensus criteria for chronic graft-versus-host disease", Leukemia, 23, pp.78~84 (2009)
- Estenne M, "Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria", J Heart Lung Transplant, 21, pp.297~310 (2002)
- Au BK, "Bronchiolitis obliterans syndrome epidemiology after allogeneic hematopoietic cell transplantation", Biol Blood Marrow Transplant, 17, pp.1072~1078 (2011)
- Nakaseko C, "Incidence, risk factors and outcomes of bronchiolitis obliter-ans after allogeneic stem cell transplantation", Int J Hematol, 93, pp.375~382 (2011)
- Socié G, "Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry", N Engl J Med, 341, pp.14~21 (1999)
- Wingard JR, "Long-term survival and late deaths after allogeneic hematopoietic cell transplantation", J Clin Oncol, 29, pp.2230~2239 (2011)
- Martin PJ, "Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation", J Clin Oncol, 28, pp.1011~1016 (2010)
- Sato M, "Time-dependent changes in the risk of death in pure bronchiolitis obliterans syndrome (BOS)", J Heart Lung Transplant, 32, pp.484~491 (2013)
- Finlen Copeland CA, "Survival after bronchiolitis obliterans syndrome among bilateral lung transplant recipients", Am J Respir Crit Care Med, 182, pp.784~789 (2010)